The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $104.59

Today's change+0.31 +0.30%
Updated December 24 1:01 PM EST. Delayed by at least 15 minutes.
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $104.59

Today's change+0.31 +0.30%
Updated December 24 1:01 PM EST. Delayed by at least 15 minutes.

Johnson & Johnson crosses above 125-day moving average

Johnson & Johnson closed up Wednesday by (U.S.)$0.31 or 0.30% to (U.S.)$104.59 and crossing above its 125-day moving average. Over the last five days, shares have gained 0.50% and are currently 4.48% off of the 52-week high. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $104.38
  • Previous close(U.S.) $104.28
  • High(U.S.) $105.33
  • Low(U.S.) $104.38
  • Bid / Ask-- / --
  • YTD % change+14.19%
  • Volume3,420,184
  • Average volume (10-day)10,061,702
  • Average volume (1-month)8,438,328
  • Average volume (3-month)8,432,929
  • 52-week range(U.S.) $86.09 to (U.S.) $109.49
  • Beta0.56
  • Trailing P/E17.31×
  • P/E 1 year forward17.50×
  • Forward PEG2.65×
  • Indicated annual dividend(U.S.) $2.80
  • Dividend yield2.68%
  • Trailing EPS(U.S.) $6.04
Updated December 24 1:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+23.27%

Based on its net profit margin of 23.27%, Johnson & Johnson is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.10%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 28, 201409/28/2014Jun 29, 201406/29/2014Mar 30, 201403/30/2014Dec 29, 201312/29/2013
Revenue18,46719,49518,11518,355
Total other revenue--------
Total revenue18,46719,49518,11518,355
Gross profit13,06813,45612,66012,400
Total cost of revenue5,3996,0395,4555,955
Total operating expense11,65713,86912,69115,605
Selling / general / administrative5,4685,4815,1835,917
Research & development2,0232,0051,8312,411
Depreciation / amortization--------
Interest expense (income), net operating130128136134
Unusual expense (income)0418338
Other operating expenses, total-1,34717195850
Operating income6,8105,6265,4242,750
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax6,8105,6265,4242,750
Income after tax4,7494,3264,7273,519
Income tax, total2,0611,300697-769
Net income4,7494,3264,7273,519
Total adjustments to net income--------
Net income before extra. items4,7494,3264,7273,519
Minority interest------0
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4,7494,3264,7273,519
Inc. avail. to common incl. extra. items4,7494,3264,7273,519
Diluted net income4,7494,3264,7273,519
Dilution adjustment--0----
Diluted weighted average shares2,8642,8742,8752,871
Diluted EPS excluding extraordinary itemsvalue per share1.661.511.641.23
Dividends per sharevalue per share0.700.700.660.66
Diluted normalized EPSvalue per share2.001.651.691.53